Cabazitaxel Teva (cabazitaxel)
- Region
- 🇪🇺 EU
- Active substance
- cabazitaxel
- Company
- Teva B.V.
- Status
- Refused
- Therapeutic area
- Prostatic Neoplasms
- CHMP opinion
- Fri 26 Apr 2019
- Application
- EMEA/H/C/004951
- ATC
- L01CD04
- Official record
- www.ema.europa.eu
Indication
Treatment of prostate cancer
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Jevtana Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Cabazitaxel Accord Authorised · Accord Healthcare S.L.U.
Follow Cabazitaxel Teva
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.